Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure

• Status: Recruiting
• Trial end date: 2020-12-20
• Target enrollment: 0
• Participant gender: All

Summary

We hypothesize that Dapagliflozin could improve the diuretic response in diabetic patients with acute decompensated heart failure owing to its diuretic effect in addition to improvement of blood glucose level without remarkable effect on kidney function or electrolytes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol; Dapagliflozin; Sodium-Glucose Transporter 2 Inhibitors

Criteria

Inclusion Criteria:

• Diabetic patient type 2 with history of chronic heart failure(HFrEF) ,there is no prespecified inclusion criterion with respect to heart failure etiology and/or ejection fraction.

Exclusion Criteria:

1. Other etiologies of fluid overload different from heart failure.

2. Hyponatremia: Sodium level below 125mmol/l

3. Unstable patients: acute coronary syndrome, cardiogenic shock .

4. Patients requiring inotropic agents or renal dialysis.

5. Pregnancy or breastfeeding period.

6. sever hepatic disease

7. GFR is less than 45 mL/min/1.73 m² .

8. Patient with diabetic ketoacidosis or non ketotic hyperosmolar.